GLSI News and Press, Greenwich LifeSciences Inc. From 09/07/21

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participa...

These Former Penny Stocks Are Turning Heads In The Stock Market This Year When it comes to trading penny stocks, you come across plenty of success stories. These typically involve big moves within short periods of time and huge windfalls for traders. They also usually entail a quick dro...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it is se...

Poster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer clinical trial. Final safety conclusions are that GP2 immunotherapy is well tolerated and that no serious adverse events rel...

Texas-based biotech Greenwich Life Sciences (NASDAQ: GLSI) is currently developing immunotherapy for use against certain types of breast cancer. Founded in 2006, the company was actually 2020's top-performing IPO, appearing on the market at $5.75 in September and hitting a low of $3...

Previously led partnering transactions and strategic analyses for multiple companies, including Roche, Pfizer, and Novartis Dr. Fischette will focus on out-licensing the Company’s lead drug candidate for recurring breast cancer, GP2, and building a clinical pipeline to comp...

Insider buying increased significantly last week. Notable Insider Buys: Landec Corporation, Super League Gaming, Inc., Cyclo Therapeutics, Inc., Greenwich LifeSciences, Inc., and Hudson Global, Inc. Notable Insider Sells: Ulta Beauty, Inc., Facebook, Inc., Fidelity National Financ...

Greenwich LifeSciences (GLSI) shares jump nearly 15% premarket after the company provides update on late-stage breast cancer treatment GP2 at the 2021 American Association for Cancer Research ((AACR)) Annual Meeting.The company plans to complete manufacturing of GP2 by the...

Galectin Therapeutics (GALT) +27% as its belapectin + Keytruda enhances tumor response in melanoma, head/neck cancer.Bit Digital (BTBT) +17%.UTStarcom Holdings (UTSI) +14%.Greenwich LifeSciences (GLSI) +15% after update on GP2 phase III clinical trial sesign.Moleculin Biotech (MBRX)...

The GP2 Phase III clinical trial design was presented in a poster during the 2021 American Association for Cancer Research (AACR) Annual Meeting, introduced by the Global Principal Investigator, Professor Mothaffar F. Rimawi of Baylor College of Medicine. The Company plans to comp...